Advertisement

Topics

Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients

22:07 EDT 27 Jun 2017 | Drugs.com

LIVONIA, Mich., June 28, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced top-line data on the LDL-C primary endpoint from the completed open label Phase 2b COBALT-1 trial. COBALT-1 evaluated gemcabene in homozygous...

Original Article: Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients

NEXT ARTICLE

More From BioPortfolio on "Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients"

Advertisement
Quick Search
Advertisement
Advertisement